VIDEO: Deucravacitinib an ‘exciting’ oral molecule for psoriasis
Click Here to Manage Email Alerts
In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the TYK2 inhibitor deucravacitinib from the Maui Derm 2024 meeting, examining its use as a treatment for psoriasis.
Chovatiya, assistant professor of dermatology at Northwestern University Feinberg School of Medicine, discussed a 3-year safety and efficacy update into the oral molecule deucravacitinib (Sotyktu, Bristol Myers Squibb) and studies looking at its use treating patients with moderate psoriasis as well as psoriatic arthritis.
“I think perhaps one of the most exciting parts of this is we have more choice for our patients, given the fact that we’ve really had so many biologics pile up and not much in the way of orals,” Chovatiya said.
Collapse
Read more about
Click Here to Manage Email Alerts